Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02171104 · ClinicalTrials.gov registry record · Phase 2
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
A Phase 2 study of Hunter Syndrome and Hurler Syndrome, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
- 1
- Study location
NCT02171104 is a Phase 2 study of Hunter Syndrome and Hurler Syndrome that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 149 participants, below the 326-participant average among 5 other Hunter Syndrome trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02171104, a Phase 2 study of Hunter Syndrome and Hurler Syndrome, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).
Conditions Studied
Interventions
- BIOLOGICAL Stem Cell Transplantation
- DRUG IMD Preparative Regimen
- DRUG Osteopetrosis Only Preparative Regimen
- DRUG Osteopetrosis Haploidentical Only Preparative Regimen
- DRUG cALD SR-A (Standard-Risk, Regimen A)
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2014-07-10 |
| Est. Completion | 2029-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02171104
The ClinicalTrials.gov registry entry for NCT02171104 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 326-participant average among 5 other Hunter Syndrome trials with a reported enrollment target (54% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hunter Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Stem Cell Transplantation is the first listed.
NCT02171104 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02171104 about?
NCT02171104 is a clinical study titled "MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis". This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patient...
What is the current status of trial NCT02171104?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2014-07-10. Estimated completion is 2029-07-14.
What conditions does trial NCT02171104 study?
This clinical trial studies the following conditions: Hunter Syndrome, Hurler Syndrome, Maroteaux Lamy Syndrome, Fucosidosis, Alpha-Mannosidosis.
What interventions are being tested in trial NCT02171104?
The interventions under investigation include: Stem Cell Transplantation (BIOLOGICAL), IMD Preparative Regimen (DRUG), Osteopetrosis Only Preparative Regimen (DRUG), Osteopetrosis Haploidentical Only Preparative Regimen (DRUG), cALD SR-A (Standard-Risk, Regimen A) (DRUG).
Who is sponsoring clinical trial NCT02171104?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02171104 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hunter Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
COMPLETED · Phase 2
-
An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment
COMPLETED · Phase 1
-
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
COMPLETED · Phase 1
-
Hunter Outcome Survey (HOS)
COMPLETED
-
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.